Skip to content
City AM
Main navigation
Download free app
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Banking
      • FTSE 100 Live
      • Tech
      • Retail
      • Insurance
      • Legal
      • Property
      • Transport
      • Markets
    • From our partners
      • Abu Dhabi Finance Week
      • AON
      • Bayes Business School
      • City of London BIDs
      • Central London Alliance CIC
      • Destination City
      • Halkin
      • Hercules
      • Olympia
      • Inside Saudi
      • Tottenham Hotspur Stadium
      • Santander X
      • YEAR SIX Dividend
    • Featured

      The London Tunnels joins JP Jenkins after ditching Euronext

      City tourism company London Tunnels decided to snub the capital for its listing after a lack of interest from UK investment banks and a charm offensive from Dutch adviser ABN Amro.

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
      • The Punter
    • From our partners
      • The Morning Briefing: SBS x City AM
      • Aramco Team Series
      • LIV Golf
    • Featured

      Pro Climbing League leans into urban boom ahead of sold-out London launch

      Breaking news event with a large crowd gathered in a city square, people holding signs, and a backdrop of modern buildings

      Submit a story

      Tell us your story.

      Submit
  • Life&Style
    • Life&Style
      • Life&Style
      • New Openings
      • Toast the City Awards
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • Media Speak Hub
    • Featured

      Drinks disasters: Three top tips to avoid being a wine wally

      Libby app interface on smartphone screen, showcasing digital library collection for e-books and audiobooks

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • City AM Events
  • Newsletters
  • Latest Paper
  • Sign In
  • Sign Out
  • My Account

FDA

  • GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer

    pharma

    GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.

    GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment in patients with myeloma, met its primary goal.
  • GSK: Good news for pharma giant as approval granted to expand vaccine use

    BUSINESS

    The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to affect younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.

    The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to include younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.
  • Investors in London-listed medical tech firm continue battle to oust top brass

    BUSINESS

    Investors in a London-listed medical technology firm are continuing their campaign to oust the company’s top brass as its share price languishes. 

    Hedge fund Saba Capital owns a significant stake in all seven trusts.
  • US regulator accepts GSK’s application to expand treatment of cancer drug

    April 24, 2024

    The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.

Trending Articles

  • Three more interest rate cuts could come, Bank of England official says

  • Brewdog: HSBC could seize brewery if no buyer found 

  • Big Four giant Deloitte forms $20bn EMEA unit amid tech disruption

  • Rolls-Royce: FTSE 100 giant set to splash £1bn on shareholders

  • Inside Sarah Ferguson’s £100k-a-week rehab with lakeside apartment and round-the-clock therapy

Subscribe

Subscribe to the City AM newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • Got a story?
  • About City AM
  • Careers
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • News
  • Markets & Economics
  • Politics
  • Opinion
  • Life&Style
  • Personal Finance
  • City AM Events
  • City Winners
  • The Punter
  • Casino

Follow us for breaking news and latest updates

  • Facebook
  • X
  • Instagram
  • LinkedIn
  • Newsletters
  • Advertising
  • About
  • Licensing
Copyright 2026 City AM Limited